Kevin Charles Gorman, a director at Neurocrine Biosciences Inc. (NASDAQ:NBIX), sold a total of 5,844 shares of the company's common stock on February 13, 2025, according to a recent SEC filing. The ...

Trump ‘is not willing to tolerate’ VAT, US president’s trade chief says, raising fears UK could face 21 per cent tax ...

Deutsche Bank’s shift to Google Cloud powers up its AI capabilities, optimising operations and slashing process times ...